Business Description
Regeneron Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US75886F1075
Compare
Compare
Traded in other countries / regions
REGN.USAREGN34.BrazilREGN.MexicoRGO.GermanyREGN.AustriaREGN.Switzerland0R2M.UK IPO Date
1991-04-02Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.3 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | 0.52 | |||||
| Interest Coverage | 62.27 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 10.74 | |||||
| Beneish M-Score | -2.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 23.3 | |||||
| 3-Year EBITDA Growth Rate | 25.8 | |||||
| 3-Year EPS without NRI Growth Rate | 27.5 | |||||
| 3-Year FCF Growth Rate | 19.7 | |||||
| 3-Year Book Growth Rate | 27.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 10.74 | |||||
| Future 3-5Y Total Revenue Growth Rate | 5.93 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.94 | |||||
| 9-Day RSI | 55.41 | |||||
| 14-Day RSI | 58.04 | |||||
| 6-1 Month Momentum % | 7 | |||||
| 12-1 Month Momentum % | 15.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.45 | |||||
| Quick Ratio | 4.8 | |||||
| Cash Ratio | 2.88 | |||||
| Days Inventory | 389.09 | |||||
| Days Sales Outstanding | 151.4 | |||||
| Days Payable | 119.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | 3.14 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.42 | |||||
| Operating Margin % | 34.2 | |||||
| Net Margin % | 33.93 | |||||
| ROE % | 19.14 | |||||
| ROA % | 14.84 | |||||
| ROIC % | 21.26 | |||||
| ROC (Joel Greenblatt) % | 53.19 | |||||
| ROCE % | 18.7 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 21.63 | |||||
| Forward PE Ratio | 18.65 | |||||
| PE Ratio without NRI | 21.63 | |||||
| Shiller PE Ratio | 31.93 | |||||
| Price-to-Owner-Earnings | 29.9 | |||||
| PEG Ratio | 0.77 | |||||
| PS Ratio | 7.43 | |||||
| PB Ratio | 3.71 | |||||
| Price-to-Tangible-Book | 3.86 | |||||
| Price-to-Free-Cash-Flow | 31.29 | |||||
| Price-to-Operating-Cash-Flow | 19.75 | |||||
| EV-to-EBIT | 17.3 | |||||
| EV-to-Forward-EBIT | 17.4 | |||||
| EV-to-EBITDA | 15.99 | |||||
| EV-to-Forward-EBITDA | 14.48 | |||||
| EV-to-Revenue | 6.61 | |||||
| EV-to-Forward-Revenue | 6.17 | |||||
| EV-to-FCF | 27.72 | |||||
| Price-to-Projected-FCF | 1.48 | |||||
| Price-to-DCF (Earnings Based) | 0.69 | |||||
| Price-to-DCF (FCF Based) | 1 | |||||
| Price-to-Median-PS-Value | 0.85 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.87 | |||||
| Price-to-Graham-Number | 1.93 | |||||
| Price-to-Net-Current-Asset-Value | 8.67 | |||||
| Price-to-Net-Cash | 38.97 | |||||
| Earnings Yield (Greenblatt) % | 5.78 | |||||
| Forward Rate of Return (Yacktman) % | 23.49 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:REGN
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Regeneron Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 12,670.8 | ||
| EPS (TTM) ($) | 37.83 | ||
| Beta | 0.27 | ||
| Volatility % | 26.06 | ||
| 14-Day RSI | 58.04 | ||
| 14-Day ATR ($) | 12.184468 | ||
| 20-Day SMA ($) | 829.2905 | ||
| 12-1 Month Momentum % | 15.36 | ||
| 52-Week Range ($) | 668 - 847.5 | ||
| Shares Outstanding (Mil) | 108.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Regeneron Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Regeneron Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Regeneron Pharmaceuticals Inc Frequently Asked Questions
What is Regeneron Pharmaceuticals Inc(REGN)'s stock price today?
The current price of REGN is $818.27. The 52 week high of REGN is $847.50 and 52 week low is $668.00.
When is next earnings date of Regeneron Pharmaceuticals Inc(REGN)?
The next earnings date of Regeneron Pharmaceuticals Inc(REGN) is 2023-11-03 Est..
Does Regeneron Pharmaceuticals Inc(REGN) pay dividends? If so, how much?
Regeneron Pharmaceuticals Inc(REGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers